Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimers Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway
HOTH Stock | USD 0.85 0.01 1.16% |
Under 61% of Hoth Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Hoth Therapeutics stock suggests that many investors are alarmed at this time. Hoth Therapeutics' investing sentiment shows overall attitude of investors towards Hoth Therapeutics.
Hoth |
Hoth Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative treatments, is proud to announce the granting of a U.S. patent for its pioneering Alzheimers treatment, HT-ALZ. This milestone patent secures the companys intellectual property rights to its novel therapeutic approach, as Hoth accelerates preparations for clinical trials.
Read at finance.yahoo.com
Hoth Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Hoth Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Hoth Therapeutics Fundamental Analysis
We analyze Hoth Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hoth Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hoth Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Hoth Therapeutics is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Hoth Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Hoth Therapeutics stock to make a market-neutral strategy. Peer analysis of Hoth Therapeutics could also be used in its relative valuation, which is a method of valuing Hoth Therapeutics by comparing valuation metrics with similar companies.
Peers
Hoth Therapeutics Related Equities
CDIO | Cardio Diagnostics | 40.74 | ||||
QNRX | Quoin Pharmaceuticals | 5.48 | ||||
ATNF | 180 Life | 3.83 | ||||
ALLR | Allarity Therapeutics | 2.94 | ||||
ADTX | Aditxt | 2.86 | ||||
ZURA | Zura Bio | 0.72 | ||||
ATXI | Avenue Therapeutics | 2.11 | ||||
NRBO | Neurobo Pharmaceuticals | 2.59 | ||||
SONN | Sonnet Biotherapeutics | 3.54 | ||||
KPRX | Kiora Pharmaceuticals | 3.57 | ||||
PHIO | Phio Pharmaceuticals | 3.91 | ||||
BDRX | Biodexa Pharmaceticals | 4.91 | ||||
VRAX | Virax Biolabs | 6.08 | ||||
REVB | Revelation Biosciences | 6.67 |
Complementary Tools for Hoth Stock analysis
When running Hoth Therapeutics' price analysis, check to measure Hoth Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hoth Therapeutics is operating at the current time. Most of Hoth Therapeutics' value examination focuses on studying past and present price action to predict the probability of Hoth Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hoth Therapeutics' price. Additionally, you may evaluate how the addition of Hoth Therapeutics to your portfolios can decrease your overall portfolio volatility.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |